New information has emerged detailing the events that led to the April 23 arrest of Seagen CEO Clay Siegall and a May 2 temporary restraining order against him, according to documents obtained by Endpoints News.

Around 3 a.m. local time on April 23, Siegall’s wife and a witness called police after he allegedly pushed her to the ground, and he was brought to jail hours later on a charge of fourth degree domestic violence gross misdemeanor, per police records from that morning. The records, as well as a restraining order and jail call logs, lay out the allegations against one of the highest-profile CEOs in biotech, who founded Seagen in the late 1990s and has built it into a $22 billion drug developer that led the ADC R&D field. Siegall was also one of the most richly compensated pharma executives in 2021, pulling in $18.1 million.

J&J is turning to longtime insiders in the executive ranks to head up its consumer division, once the company completes its spinout: Thibaut Mongon, who will serve as CEO, and Paul Ruh, who will operate as CFO of the yet-to-be-named consumer health company.

Mongon has been on the payroll for the past 20 years, rising through the ranks since joining in 2000, according to his LinkedIn page. He reached the heights of executive vice president and worldwide chairman of consumer health at J&J and has been in that position since 2019.

Legal trouble is mounting higher for Usama Malik, the former Immunomedics CFO accused of sharing insider information with his then-girlfriend and a number of relatives.

Malik was indicted Wednesday morning on three counts of insider trading, securities fraud and securities fraud conspiracy, the US Department of Justice announced.

The former CFO spent nearly four years at Immunomedics, helping steer the company to a $21 billion buyout by Gilead back in 2020. The ink was barely dry before he jumped over to the helm at precision oncology company Fore Bio — but that didn’t last long.

Joseph Kim, the longtime CEO who’s become almost synonymous with Inovio, is leaving the beleaguered company.

Stepping down to make room for Jacqueline Shea — who first joined Inovio as COO in 2019 — Kim leaves behind a legacy of boisterous claims and promises about DNA vaccines over decades and a habit of capitalizing on pandemics but no approved product to show for it.

Shea will be overseeing a change in direction as Inovio, a laggard in the Covid-19 vaccine race, shutters a Phase III trial in favor of a booster strategy.

Biotech industry leaders want the drug development world to stand up and ensure employees have access to abortions after a draft ruling last week revealed the nation’s highest court might overturn a nearly five-decade-old ruling, known by two names: Roe v. Wade.

“We have to make noise, for one thing, which is effective, but also encourage people to take some sort of action,” Paul Hastings told Endpoints News. Last week, the Nkarta CEO and BIO chair called on his fellow biotech companies to help pay for travel expenses for employees in states hindering access to reproductive health.

The Longeveron CEO who helped take the biotech public is now set to resign.

Geoff Green, Longeveron’s chief executive since November 2020, will step down effective June 1 to pursue new opportunities, the company announced Monday afternoon. In his place, current CMO Chris Min will serve as interim CEO while Longeveron conducts a search for a permanent chief.

Green will remain a consultant for an undetermined time to help ensure a smooth transition, the company added. Shares $LGVN were down about 5% in post-market trading. He joins a cadre of biotech executives leaving their posts in the wake of a bear market that continues to batter the sector.

A new era is unfolding at Adimab.

Fifteen years after he co-founded the antibody discovery shop, Tillman Gerngross is stepping down as CEO — handing the reins to Philip Chase, general counsel. Stepping away from day-to-day operations, the company noted he will now move to the strategic role of executive chairman of the board.

It’s the second departure for Gerngross within the past few months. Back in February, the longtime Dartmouth professor resigned from the CEO post at Adagio, the Covid-focused Adimab spinout.

Clay Siegall was placed on leave from his posts as CEO and chairman of prominent Seattle-area biotech Seagen after an arrest by the Edmonds Police Department on April 23.

At 3:41 a.m. local time on April 23, police were dispatched to Siegall’s home, where he was arrested on charge of 4th degree assault domestic violence gross misdemeanor, the police department’s public information officer confirmed to Endpoints News. Siegall had a court appearance the next day, the officer said, noting the investigation is now in the court’s hands.